Table 2 Post-Event Pharmacologic Treatment of Participants With and Without Heart Failure
Hospitalized Heart Failure* | Treated, Nonhospitalized Heart Failure* | Without Heart Failure† | ||||
|---|---|---|---|---|---|---|
C | D | C | D | C | D | |
No. of participants | 232 | 281 | 93 | 145 | 14493 | 8347 |
Post-event medication | ||||||
Blinded medication, (%) | 83 (35.8) | 126 (44.8) | 54 (58.1) | 93 (64.1) | 11247 (77.6) | 6096 (73.0) |
Open-label diuretic (%) | 135 (58.2) | 180 (64.0) | 57 (61.3) | 98 (67.6) | 1279 (8.8) | 1153 (13.8) |
Open-label ACE-inhibitor (%) | 90 (38.8) | 114 (40.5) | 31 (33.3) | 44 (30.3) | 1154 (8.0) | 826 (9.9) |
Open-label beta-blocker (%) | 33 (14.2) | 38 (13.5) | 18 (19.4) | 32 (22.1) | 3149 (21.7) | 2016 (24.0) |
Open-label diuretic, ACE-inhibitor or beta-blocker (%) | 169 (72.8) | 210 (74.8) | 72 (77.4) | 119 (82.1) | 4829 (33.3) | 3347 (40.1) |